Skip to main content
Clinical Trials/NCT03105882
NCT03105882
Withdrawn
Not Applicable

Pilot Study of Clinical Safety and Feasibility of the Neuro-Spinal Scaffold for the Treatment of Complete (AIS A) Traumatic Acute Spinal Cord Injury at the C5 - T1 Neurological Levels

InVivo Therapeutics1 site in 1 countryMarch 30, 2017

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Traumatic Cervical Acute Spinal Cord Injury
Sponsor
InVivo Therapeutics
Locations
1
Primary Endpoint
Incidence of all Adverse Device Effects of any kind/seriousness.
Status
Withdrawn
Last Updated
8 years ago

Overview

Brief Summary

Pilot Study of Clinical Safety and Feasibility of the Neuro-Spinal ScaffoldTM for the Treatment of Complete (AIS A) Traumatic Acute Spinal Cord Injury at the C5-T1 Neurological Levels The purpose of this study is to support an expansion to support marketing applications as well as future studies.

Registry
clinicaltrials.gov
Start Date
March 30, 2017
End Date
March 15, 2018
Last Updated
8 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • 16-70 years of age, inclusive
  • AIS A classification of traumatic spinal cord injury with a neurological level within C5-T1 inclusive
  • Recent injury
  • Non-penetrating SCI

Exclusion Criteria

  • Terminally ill subjects not likely to be able to participate in follow-up
  • Incomplete spinal cord injury (AIS B, C, D, and E injuries)
  • No identifiable intra-spinal cavity following myelotomy/irrigation in the contused spinal cord in which a Scaffold can be placed
  • Spinal cord injury associated with significant traumatic brain injury or coma that
  • Radiographic or visual evidence of parenchymal dissociation or anatomic transection as determined by the Investigator where the contusion completely bridges a full cross-section of the spinal cord
  • Subjects with spinal cord injuries directly due to gunshot, knife, or other penetrating wounds

Outcomes

Primary Outcomes

Incidence of all Adverse Device Effects of any kind/seriousness.

Time Frame: 6 Months

Study Sites (1)

Loading locations...

Similar Trials